ANA 2021: Fremanezumab Effective Long-Term Against Chronic and Episodic Migraine That Failed to Respond to Multiple Drug Classes
The study included patients who had switched from quarterly to monthly fremanezumab.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.